BIODELIVERY SCIENCES INTERNATIONAL INC
DelistedCIK 1103021fmd_1KPQBX9C064EAJPZ8V2EJ9DS9XManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Dec 31, 2021, 48 periods
Latest annual · FY2021
Millions- Total revenues
- 167
- Gross profit
- 143
- Operating income
- 37
- Net income
- 85
- Free cash flow
- 41
Latest quarter · Q4 FY2021
Millions- Total revenues
- 43
- Gross profit
- 36
- Operating income
- 9
- Net income
- 64
- Free cash flow
- 14
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2018 to FY2021
- +44.2%
- Revenue, 5 yearsFY2016 to FY2021
- +60.7%
- Net income, 5 yearsFY2016 to FY2021
- n/m
BIODELIVERY SCIENCES INTERNATIONAL INC financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2021 | FY2020 | Change | Source |
|---|---|---|---|---|
| Revenue | $166.7 million | $156.5 million | +6.5% | 10-K 2022-03-09 · proof |
| Gross profit | $143.3 million | $131.8 million | +8.7% | 10-K 2022-03-09 · proof |
| Operating income | $37.1 million | $33 million | +12.6% | 10-K 2022-03-09 · proof |
| Net income | $84.9 million | $25.7 million | +230.1% | 10-K 2022-03-09 · proof |
| Cash from operating activities | $41 million | $25 million | +64.3% | 10-K 2022-03-09 · proof |
| Free cash flow | $40.6 million | $25 million | +62.7% | 10-K 2022-03-09 · proof |
| Total assets | $324.6 million | $239.9 million | +35.3% | 10-K 2022-03-09 · proof |
| Total liabilities | $136.8 million | $131.7 million | +3.9% | 10-K 2022-03-09 · proof |
| Cash and cash equivalents | $114.3 million | $111.6 million | +2.4% | 10-K 2022-03-09 · proof |
- What was BIODELIVERY SCIENCES INTERNATIONAL INC's revenue in fiscal 2021?
- BIODELIVERY SCIENCES INTERNATIONAL INC reported revenue of $166.7 million for fiscal 2021 (the year ended Dec 31, 2021), against $156.5 million the year before (+6.5%). Source: the 10-K filed with the SEC on Mar 9, 2022. SEC
- What was BIODELIVERY SCIENCES INTERNATIONAL INC's gross profit in fiscal 2021?
- BIODELIVERY SCIENCES INTERNATIONAL INC reported gross profit of $143.3 million for fiscal 2021 (the year ended Dec 31, 2021), against $131.8 million the year before (+8.7%). Source: the 10-K filed with the SEC on Mar 9, 2022. SEC
- What was BIODELIVERY SCIENCES INTERNATIONAL INC's operating income in fiscal 2021?
- BIODELIVERY SCIENCES INTERNATIONAL INC reported operating income of $37.1 million for fiscal 2021 (the year ended Dec 31, 2021), against $33 million the year before (+12.6%). Source: the 10-K filed with the SEC on Mar 9, 2022. SEC
- What was BIODELIVERY SCIENCES INTERNATIONAL INC's net income in fiscal 2021?
- BIODELIVERY SCIENCES INTERNATIONAL INC reported net income of $84.9 million for fiscal 2021 (the year ended Dec 31, 2021), against $25.7 million the year before (+230.1%). Source: the 10-K filed with the SEC on Mar 9, 2022. SEC
- What was BIODELIVERY SCIENCES INTERNATIONAL INC's cash from operating activities in fiscal 2021?
- BIODELIVERY SCIENCES INTERNATIONAL INC reported cash from operating activities of $41 million for fiscal 2021 (the year ended Dec 31, 2021), against $25 million the year before (+64.3%). Source: the 10-K filed with the SEC on Mar 9, 2022. SEC
- What was BIODELIVERY SCIENCES INTERNATIONAL INC's free cash flow in fiscal 2021?
- BIODELIVERY SCIENCES INTERNATIONAL INC reported free cash flow of $40.6 million for fiscal 2021 (the year ended Dec 31, 2021), against $25 million the year before (+62.7%). Source: the 10-K filed with the SEC on Mar 9, 2022. SEC
- What are BIODELIVERY SCIENCES INTERNATIONAL INC's total assets?
- As of Dec 31, 2021, BIODELIVERY SCIENCES INTERNATIONAL INC reported total assets of $324.6 million, against $239.9 million a year earlier (+35.3%). Source: the 10-K filed with the SEC on Mar 9, 2022. SEC
- What are BIODELIVERY SCIENCES INTERNATIONAL INC's total liabilities?
- As of Dec 31, 2021, BIODELIVERY SCIENCES INTERNATIONAL INC reported total liabilities of $136.8 million, against $131.7 million a year earlier (+3.9%). Source: the 10-K filed with the SEC on Mar 9, 2022. SEC
- What are BIODELIVERY SCIENCES INTERNATIONAL INC's cash and cash equivalents?
- As of Dec 31, 2021, BIODELIVERY SCIENCES INTERNATIONAL INC reported cash and cash equivalents of $114.3 million, against $111.6 million a year earlier (+2.4%). Source: the 10-K filed with the SEC on Mar 9, 2022. SEC
Read from the FinancialMD API on Nov 14, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1103021&period_type=annual&limit=5"Information only, not investment advice.